The size of the Acute Ischemic Stroke Treatment & Diagnosis Market in Europe is predicted to worth USD 1012.81 million by 2025 from USD 749.73 million in 2020 and estimated to be growing at a CAGR of 6.2% from 2020 to 2025.
Acute Ischemic stroke can be defined as loss of function in certain parts of the brain due to a lack of blood supply to the brain.
Europe Ischemic stroke diagnostics and treatment market is driven by key factors such as increasing prevalence of acute ischemia stroke cases, technological advancements in surgical procedures along with rising geriatric population, growing demand for minimally invasive procedures and growth in healthcare spending whereas excessive usage of medication for the treatment of ischemic stroke and high cost of surgical procedures are restraining the market growth.
This research report on the Europe Acute Ischemic Stroke Treatment & Diagnosis Market is segmented and sub-segmented into the following categories:
By Diagnostic Type:
By Surgery Type:
By Country:
On the basis of surgery type, Carotid Endarterectomy is the largest segment accounting for a share of approximately XX% due to its high success rate, short treatment duration, and easy availability.
On the basis of region, Europe is the second largest for Acute Ischemic Stroke Diagnosis and Treatment devices accounting for a share of approximately XX% in 2019 due to favorable government initiatives, technological innovations. Within Europe, the United Kingdom accounted for the largest share and is estimated to retain its strong share while Germany is estimated to be the fastest-growing due to increasing prevalence
Leading companies in the Europe Acute Ischemic Stroke Diagnosis & Treatment Market profiled in this report are Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.) and Hitachi, Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Type
5.1.1 Computed Tomography
5.1.2 Magnetic Resonance Imaging
5.1.3 Ultrasound
5.1.4 Cerebral angiography
5.1.5 Nuclear Imaging
5.2 Surgery Type
5.2.1 Carotid Endarterectomy
5.2.2 Angioplasty
5.2.3 Endovascular Mechanical Thrombectomy
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Covidien plc
8.3 Johnson & Johnson
8.4 Penumbra, Inc.
8.5 Philips Healthcare
8.6 GE Healthcare
8.7 Hitachi, Ltd.
8.8 Siemens Healthcare
8.9 Stryker Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
